Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure

This article was originally published in The Gray Sheet

Executive Summary

Friends of Cancer Research proposes realignment of FDA to be organized more around disease areas and less around the distinctions between drugs, devices and biologics. The idea has generated some support from former commissioners and current officials, while others warn of unintended consequences.

Advertisement

Related Content

FDA's New Cross-Cutting Oncology Center Gets Pazdur As Lead
President Urges Breaking Down Of Drug, Device Distinctions, Regulatory Barriers
FDA Funding Proposal Includes Cross-Cutting Oncology Focus, Disappoints Budget Advocates
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Oncology Drug Reviews To Be Restructured As Office Shifts Away From Divisions Organized Around Molecule Size

Topics

Advertisement
UsernamePublicRestriction

Register

MT034410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel